To determine the capacity of the small molecule MET inhibitor (MK-8033) to inhibit MET phosphorylation in uveal melanoma cell lines with a GNAQ mutation versus no GNAQ mutation (hereafter “wild-type”), cells were treated with MK-8033 at either 0, 1 or 2.5 μM concentrations (Figure 2A). This evidence concerns the gene MET and uveal melanoma.